歐洲肝纖維化治療市場規模、份額和趨勢分析報告—產業概況和2032年預測

Customize Your Report Customize Your Report 立即购买 立即购买 免费样本报告 免费样本报告
Home Healthcare Europe Liver Fibrosis Treatment Market
请求目录 请求目录 与分析师交谈 与分析师交谈 免费样本报告 免费样本报告 购买前请咨询 提前咨询 立即购买 立即购买

歐洲肝纖維化治療市場規模、份額和趨勢分析報告—產業概況和2032年預測

  • Healthcare
  • Published Report
  • Apr 2025
  • Europe
  • 350 页面
  • 桌子數： 875
  • 图号： 42
  • Author : Sachin Pawar
立即购买 立即购买 索取樣品 索取樣品
Nucleus Nucleus

通过敏捷供应链咨询解决关税挑战

供应链生态系统分析现已成为 DBMR 报告的一部分

Europe Liver Fibrosis Treatment Market

市场规模（十亿美元）

CAGR :  % Diagram

Chart Image USD 5.06 Billion USD 11.04 Billion 2024 2032
Diagram Forecast Period
 2025 –2032
Diagram Market Size (Base Year)
 USD 5.06 Billion
Diagram Market Size (Forecast Year)
 USD 11.04 Billion
Diagram CAGR
 %
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
Request For Unlock

歐洲肝纖維化治療市場，按治療類型（藥物和手術/療法）、分期（F2、F1、F3 和 F4）、適應症（非酒精性脂肪性肝炎 (NASH)、乙肝和丙肝誘發的纖維化、酒精性肝病 (ALD)、自體免疫性肝病、遺傳性疾病等）、性別（男性及女性門診（診所）、診所產業趨勢與預測（至 2032 年）

歐洲肝纖維化治療市場

歐洲肝纖維化治療市場規模

  • 2024 年歐洲肝纖維化治療市場價值為50.6 億美元，預計到 2032 年將達到110.4億美元
  • 在 2025 年至 2032 年的預測期內，市場可能以10.3% 的複合年增長率成長，主要原因是消費者對自然健康解決方案的認識不斷提高
  • 這種增長是由肝病盛行率上升等因素推動的。此外，經濟負擔能力也推動了酒精消費量的上升。

歐洲肝纖維化治療市場分析

  • 肝病數量的不斷增加使得需要有效治療方案的患者群體不斷擴大，尤其是B型肝炎和C肝等疾病。酒精消費量增加、不健康的飲食習慣以及肥胖率上升等因素都導致越來越多的人被診斷出患有這些肝病
  • 隨著肝損傷的加重，肝纖維化的風險也會增加，這給醫療保健系統提供有效治療方案帶來了沉重的負擔。這種不斷增長的需求推動了標靶療法的開發和普及，推動了市場成長，因為醫療保健提供者正在尋求管理這種疾病的創新解決方案
  • 此外，醫療保健從業人員和公眾意識的提高使得更多的人在肝病早期階段得到篩檢和診斷。診斷技術的進步，包括非侵入性影像和血液測試，使得在疾病進展過程中能夠更早發現肝纖維化。這種早期檢測可以及時幹預，刺激對有效逆轉或控制肝纖維化的創新治療的需求
  • 例如，2023年8月，根據NCBI發表的一篇文章，肝病每年導致200萬人死亡，佔所有死亡人數的4%（全球每25人死亡中就有1人死於肝病）；大約三分之二的肝臟相關死亡發生在男性身上。這項令人震驚的統計數據凸顯了對有效治療方案的迫切需求，並凸顯了肝病帶來的沉重公共衛生負擔，進一步促使醫療保健系統和製藥公司優先開發專門針對肝纖維化及其根本原因的創新療法
  • 因此，製藥公司和醫學研究人員被迫投資開發新的治療方案，從而推動市場發展，因為利害關係人的目標是對抗肝病及其相關併發症的發生率上升。

報告範圍和歐洲肝纖維化治療市場細分         

屬性

全球肝纖維化治療市場關鍵市場洞察

涵蓋的領域
  • 按治療類型
    • 藥物
    • 手術/治療
  • 階段
    • F2
    • F1
    • F3
    • F4
  • 適應症
    • 非酒精性脂肪性肝炎（NASH）
    • 乙肝和丙肝引起的纖維化
    • 酒精性肝病（ALD）
    • 自體免疫性肝病
    • 遺傳性疾病
    • 其他的
  • 性別
    • 男性
    • 女性
  • 最終用戶
  • 醫院
    • 專科診所
    • 診所
    • 流動和研究中心
    • 其他的
  • 分銷管道
    • 直接投標
    • 零售銷售

覆蓋國家
  • 北美洲
    • 蝨
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    •  法國
    •  英國
    •  義大利
    •  西班牙
    •  瑞士
    •  俄羅斯
    •  比利時
    •  荷蘭
    •  火雞
    •  波蘭
    •  瑞典
    •  挪威
    •  丹麥
    •  芬蘭
    •  歐洲其他地區
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 新加坡
    • 泰國
    • 印尼
    • 馬來西亞
    • 台灣
    • 紐西蘭
    • 菲律賓
    • 越南
    • 亞太其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 中東和非洲
    • 南非
    •  沙烏地阿拉伯
    •  阿聯酋
    •  埃及
    •  以色列
    •  科威特
    •  卡達
    •  阿曼
    •  中東和非洲其他地區

主要市場參與者
  • F. Hoffmann-La Roche Ltd（瑞士）
  • 雅培（美國）
  • 拉雷農醫療保健私人有限公司有限公司（印度）
  • GENFIT SA（法國）
  • Madrigal Pharmaceuticals（美國）
  • Aligos Therapeutics（美國）
  • 輝瑞公司（美國）
  • Enanta Pharmaceuticals, Inc.（美國）
  • 百時美施貴寶公司（美國）
  • Vertex Pharmaceuticals Incorporated（美國）
  • 武田藥品工業株式會社（日本）
  • Hepion Pharmaceuticals（美國）
  • Echosens（法國）
  • Galectin Therapeutics, Inc.（美國）
  • Conatus Pharmaceuticals（美國）
  • Tvardi Therapeutics（美國）
  • Viking Therapeutics（美國）
  • Calliditas Therapeutics AB（瑞典）
  • Novomedix（美國）
  • Galecto Biotech（丹麥）
  • Pilant Therapeutics, Inc.（美國）
  • Sagimet Biosciences（美國）
  • Gyre Therapeutics, Inc.（美國）
  • Akero Therapeutics, Inc.（美國）
  • CureVac SE（德國）
  • 諾和諾德公司（丹麥）
  • 益普生製藥（法國）
  • AdAlta有限公司（澳洲）
  • Alentis Therapeutics AG（瑞士）
  • 吉利德科學公司（美國）
  • 艾伯維公司（美國）
  • 默克公司（美國）
  • 諾華公司（瑞士）
  • Intercept Pharmaceuticals, Inc.（美國）

市場機會
  • 肝纖維化管理的新興技術和先進治療方法
  • 肝纖維化治療藥物研發管線進展
  • 主要參與者之間的策略併購

加值資料資訊集

除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括進出口分析、生產能力概覽、生產消費分析、價格趨勢分析、氣候變遷情景、供應鏈分析、價值鏈分析、原材料/消耗品概覽、供應商選擇標準、PESTLE 分析、波特分析和監管框架。

歐洲肝纖維化治療市場趨勢

“肝病盛行率不斷上升”

  • 肝病盛行率的不斷上升正成為一個重要的全球健康議題，大大增加了全球醫療負擔
  • 過量飲酒、肥胖率上升、病毒性肝炎感染以及不健康的生活方式等因素導致脂肪肝、肝硬化和肝癌等疾病的發生率激增
  • 非酒精性脂肪肝（NAFLD）的發生率不斷上升，特別是與糖尿病和代謝症候群相關的發生率也令人擔憂。因此，對早期診斷、有效治療方案和公共衛生措施的需求日益增加。預計這一趨勢將推動肝病治療市場的創新和成長

歐洲肝纖維化治療市場動態

驅動程式

“酒精消費量上升”

  • 酒精消費量的增加是全球肝纖維化治療市場的重要因素，因為它與肝病的發生率直接相關，尤其是酒精性肝病（ALD）
  • 隨著越來越多的人定期大量飲酒，罹患肝臟相關併發症（包括肝纖維化和肝硬化）的風險顯著增加
  • 慢性酒精中毒會導致發炎、脂肪堆積，最終導致肝臟纖維化，因為肝臟會反覆受到損傷和修復
  • 酒精相關肝病的盛行率日益上升，迫切需要有效的治療和管理策略來幫助減輕肝損傷並改善患者的預後。

例如，

  • 2024 年 10 月，根據《國際精神衛生系統期刊》發表的一篇文章，酒精消費的盛行率在基線和追蹤中分別為 54.5% 和 47.7%。此外，12%的男性表示剛開始喝酒。酒精消費的普遍性導致全球肝纖維化發生率上升，可能影響市場成長
  • 2024 年 6 月，根據 STAT 的數據，與酒精有關的死亡人數呈上升趨勢，專家尤其擔心年輕人和女性的死亡人數會增加。 2019 年至 2020 年間，美國與酒精相關的死亡人數激增 25.5%，佔所有死亡人數的 3%。此外，酒精相關死亡人數增加最多的是25至34歲和35至44歲的人群，這兩個群體的死亡人數都增加了37%以上
  • 此外，社會對酒精消費的接受度和正常化程度不斷提高，尤其是在年輕人群體中，進一步加劇了這個問題，導致更多人面臨肝纖維化的風險
  • 這一趨勢促進了肝纖維化治療市場的成長，並強調了旨在減少酒精消費和預防肝病的公共衛生舉措的重要性

機會

“肝纖維化管理的新興技術和先進治療方法”

  • 基因治療、標靶分子治療和生物製劑等新興技術正在改變治療格局
  • 最近的創新集中在專門針對纖維化進展途徑的藥物，例如 FXR 激動劑、TGF-β 抑制劑和抗發炎劑。此外，彈性成像等非侵入性診斷工具正在改善早期檢測
  • 這些進步為 NASH（非酒精性脂肪性肝炎）和肝硬化等疾病提供了更有效、個人化的治療，從而改善了患者的治療效果
  • 2024年2月，Springer Nature發表了一篇文章，文章回顧了診斷和抑制肝纖維化的新興方法。進展包括非侵入性生物標記、影像技術和間質幹細胞等細胞療法。吡非尼酮和奧貝膽酸等有前景的抗纖維化藥物，以及組織工程、奈米技術和微流體模型的創新，展現出個人化、精準治療的潛力
  • NCBI 2021 年 9 月的一篇文章強調，肝纖維化治療的新興技術專注於針對肝星狀細胞活化等分子途徑的先進療法。基因治療、生物製劑、小分子抑制劑和非侵入性診斷等創新改善了早期檢測和治療。幹細胞療法和組織工程也為逆轉纖維化和促進康復提供了希望
  • 隨著治療策略和診斷技術的不斷發展，肝纖維化治療正在迅速發展
  • 這些創新為更好地管理肝病帶來了希望，確保患者能夠獲得更有效、個人化、副作用更少的治療，最終改善全球健康狀況

限制/挑戰

“對肝病的認識有限”

  • 對肝臟疾病的認識有限，阻礙了早期診斷和適當的干預。許多人仍然沒有意識到與肝臟疾病相關的風險因素和症狀，常常將模糊的疾病跡象歸咎於其他不太嚴重的問題
  • 缺乏知識會延遲醫療諮詢，直到疾病發展到晚期階段，例如肝纖維化或肝硬化，此時治療方案變得更加複雜且效果更差
  • 因此，晚期診斷降低了成功治療的可能性，並透過限制尋求及時治療的患者數量來限制整體市場的成長

例如，

  • 2024年4月，魯賓表示，患者直到疾病發展到關鍵階段才意識到自己的病情，這迫切需要重新評估肝臟健康意識、檢測和管理的方法。然而，肝臟健康管理的一個重大障礙是對肝臟疾病及其相關風險因素的了解有限
  • 2021 年 7 月，根據一項涉及五項全國健康和營養檢查調查中的 11,700 名成年人（18 歲以上）的研究，美國近 96% 的 NAFLD 成年人不知道自己患有肝病，尤其是年輕人。因此，提高對肝臟健康的認識和教育對於改善患者預後、促進更積極主動的肝纖維化管理和治療市場擴張至關重要
  • 2021年1月，Springer Nature通報，在研究論文《2型糖尿病患者缺乏對肝臟器官損害的認識》中進行的研究分析中，納入的825名患者中，8.1%（95% CI 5.1%-12.7%）的脂肪變性患者知道自己患有肝臟疾病。此外，在美國具有全國代表性的 2 型糖尿病成年人樣本中，晚期肝纖維化的盛行率很高。不到 20% 的晚期纖維化患者意識到自己患有肝臟疾病
  • 認知不足會阻礙患者的潛在治療效果，並透過減少早期參與醫療服務的人數來抑制市場成長
  • 因此，提高對肝臟健康的認識和教育對於改善早期診斷、提高治療效果以及最終促進更強的肝纖維化治療市場至關重要

歐洲肝纖維化治療市場範圍

市場根據治療類型、階段、適應症、最終用戶和分銷管道進行細分。

分割

細分

按治療類型
  • 治療類型
    • 藥物
    • 手術/治療

按階段
  • 階段
    • F2
    • F1
    • F3
    • F4

按適應症
  • 適應症
    • 非酒精性脂肪性肝炎（NASH）
    • 乙肝和丙肝引起的纖維化
    • 酒精性肝病（ALD）
    • 自體免疫性肝病
    • 遺傳性疾病
    • 其他的。

按最終用戶
  • 最終用戶
    • 醫院
    • 專科診所
    • 診所
    • 流動和研究中心
    • 其他的

按分銷管道
  • 分銷管道
    • 直接投標
    • 零售銷售

歐洲肝纖維化治療市場區域分析

“德國是大型主機市場的主導地區”

  • 德國在歐洲肝纖維化治療市場處於領先地位，這得益於其強大的醫療基礎設施、肝臟相關疾病的高發病率以及對早期診斷和乾預策略的高度重視
  • 該國受益於廣泛的醫療保健覆蓋、完善的報銷政策以及對非侵入性診斷和治療方案日益增長的需求。
  • 德國在臨床研究方面的領導地位及其在肝病宣傳運動中的積極參與進一步支持了市場成長
  • 先進療法的日益普及、患者意識的不斷提高以及政府應對慢性肝病的舉措，促成了德國在該地區佔據主導地位

“預計德國將實現最高成長率”

  • 德國也是成長最快的市場，這得益於纖維化生物標記的不斷創新、製藥公司加大研發投入以及酒精相關和非酒精性脂肪肝疾病發病率的上升
  • 這些因素共同使德國成為歐洲肝纖維化治療的中心樞紐，使其成為該地區最大且成長最快的市場

歐洲肝纖維化治療市佔率

市場競爭格局提供了競爭對手的詳細資訊。詳細資訊包括公司概況、公司財務狀況、收入、市場潛力、研發投資、新市場計劃、歐洲業務、生產基地和設施、生產能力、公司優勢和劣勢、產品發布、產品寬度和廣度、應用主導地位。以上提供的數據點僅與公司對市場的關注有關。

市場中主要的市場領導者有：

  • F. Hoffmann-La Roche Ltd（瑞士）
  • 雅培（美國）
  • 拉雷農醫療保健私人有限公司有限公司（印度）
  • GENFIT SA（法國）
  • Madrigal Pharmaceuticals（美國）
  • Aligos Therapeutics（美國）
  • 輝瑞公司（美國）
  • Enanta Pharmaceuticals, Inc.（美國）
  • 百時美施貴寶公司（美國）
  • Vertex Pharmaceuticals Incorporated（美國）
  • 武田藥品工業株式會社（日本）
  • Hepion Pharmaceuticals（美國）
  • Echosens（法國）
  • Galectin Therapeutics, Inc.（美國）
  • Conatus Pharmaceuticals（美國）
  • Tvardi Therapeutics（美國）
  • Viking Therapeutics（美國）
  • Calliditas Therapeutics AB（瑞典）
  • Novomedix（美國）
  • Galecto Biotech（丹麥）
  • Pilant Therapeutics, Inc.（美國）
  • Sagimet Biosciences（美國）
  • Gyre Therapeutics, Inc.（美國）
  • Akero Therapeutics, Inc.（美國）
  • CureVac SE（德國）
  • 諾和諾德公司（丹麥）
  • 益普生製藥（法國）
  • AdAlta有限公司（澳洲）
  • Alentis Therapeutics AG（瑞士）
  • 吉利德科學公司（美國）
  • 艾伯維公司（美國）
  • 默克公司（美國）
  • 諾華公司（瑞士）
  • Intercept Pharmaceuticals, Inc.（美國）

歐洲肝纖維化治療市場的最新發展

  • 2024年6月，吉利德科學在米蘭舉行的2024年歐洲肝病研究協會（EASL）大會上展示了這項新研究，重點關注原發性膽汁性膽管炎（PBC）、B型肝炎（HBV）、丁型肝炎病毒（HDV）等肝病。主要演講將包括 ASSURE 研究 seladelpar 治療 PBC 的長期數據、替諾福韋用於預防 HBV 肝癌的結果，以及 MYR204 和 MYR301 研究 Hepcludex 治療 HDV 的發現。這項研究凸顯了吉利德致力於推進肝病治療方案的承諾
  • 2024 年 10 月，Intercept Pharmaceuticals, Inc 討論了他們為探索原發性膽汁性膽管炎 (PBC) 護理中的種族差異和差距而做出的持續努力。該公司正在解決不同人群在 PBC 的診斷、治療和管理方面可能面臨的不同挑戰。透過探索這些差異，Intercept 旨在改善所有患者獲得護理和治療結果的機會，從而可能減少有效治療肝病（包括纖維化）的障礙
  • 2022年11月，美國食品藥物管理局（FDA）批准Vemlidy（替諾福韋艾拉酚胺）用於治療12歲及以上患有代償性肝病的兒科患者的慢性乙型肝炎病毒（HBV）感染。此次批准擴大了 Vemlidy 的使用範圍，該藥物最初於 2016 年獲批用於治療患有慢性乙型肝炎的成年人。這項批准基於一項 2 期臨床試驗，該試驗證明了 Vemlidy 對這群年輕患者的有效性和安全性
  • 2022年9月，吉利德科學完成了英國生技公司MiroBio的收購，該公司專注於透過針對免疫抑制受體的激動劑來恢復免疫平衡。此次收購價值約 4.05 億美元，為吉利德提供了 MiroBio 的發現平台及其免疫抑制受體激動劑產品組合。 MiroBio 的主要研究抗體 MB272 針對免疫細胞來抑制發炎免疫反應，目前正處於第一階段臨床試驗階段。這項收購增強了吉利德在治療慢性免疫介導疾病方面的努力
  • 2021年3月，吉利德科學與諾和諾德啟動2b期臨床試驗，擴大在非酒精性脂肪性肝炎（NASH）治療的合作。該研究調查了諾和諾德公司的 GLP-1 受體激動劑 semaglutide 與吉利德的 cilofexor（一種 FXR 激動劑）和 firsocostat（一種 ACC 抑制劑）聯合治療 NASH 導致的肝硬化患者的安全性和有效性。該試驗將評估這些療法對肝纖維化和 NASH 消退的影響，預計將於 2021 年下半年開始招募

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

Sample Image Click on image to enlarge
  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE EUROPE LIVER FIBROSIS TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 MULTIVARIATE MODELLING

2.6 TREATMENT TYPE LIFELINE CURVE

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSIS

4.2 PORTERS FIVE FORCES ANALYSIS

4.2.1 LIVER TRANSPLANTATION VOLUME AND THEIR COST FOR LIVER FIBROSIS BY COUNTRY

4.2.2 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES FOR LIVER FIBROSIS: VOLUME AND COST BY COUNTRY

4.2.3 PARTIAL HEPATECTOMY (LIVER RESECTION) COST BY COUNTRY

4.2.4 CELL-BASED THERAPY COST FOR LIVER FIBROSIS TREATMENT BY COUNTRY

4.3 EPIDEMIOLOGY

4.3.1 INCIDENCE OF ALL BY GENDER

4.3.2 TREATMENT RATE

4.3.3 TREATMENT RATE

4.3.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

4.3.5 PATIENT TREATMENT SUCCESS RATES

4.4 MARKETED DRUG ANALYSIS

4.5 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

4.5.1 PATIENT FLOW DIAGRAM

4.5.2 KEY PRICING STRATEGIES

4.5.3 KEY PATIENT ENROLLMENT STRATEGIES

5 EUROPE LIVER FIBROSIS TREATMENT MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF LIVER DISEASES

6.1.2 RISING CONSUMPTION OF ALCOHOL

6.1.3 RISING LIVER TRANSPLANTATION RATES

6.1.4 GROWING INCIDENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) & NASH

6.2 RESTRAINTS

6.2.1 LIMITED AWARENESS OF LIVER DISEASES

6.2.2 REGULATORY CHALLENGES

6.3 OPPORTUNITIES

6.3.1 EMERGING TECHNOLOGIES AND ADVANCED TREATMENTS IN LIVER FIBROSIS MANAGEMENT

6.3.2 PROGRESS IN PIPELINE PRODUCTS FOR LIVER FIBROSIS TREATMENT

6.3.3 STRATEGIC MERGERS AND ACQUISITIONS AMONG THE KEY PLAYERS

6.4 CHALLENGES

6.4.1 LACK OF EFFECTIVE AND APPROVED ANTI-FIBROTIC DRUGS

6.4.2 HIGH COST OF TREATMENTS IN LIVER FIBROSIS CARE

7 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE

7.1 OVERVIEW

7.2 MEDICATION

7.2.1 ANTIVIRAL AGENTS

7.2.1.1 VELPATASVIR/SOFOSBUVIR

7.2.1.2 TENOFOVIR

7.2.1.3 LEDIPASVIR/SOFOSBUVIR

7.2.1.4 SOFOSBUVIR

7.2.1.5 ENTECAVIR

7.2.2 ANTIFIBROTIC AGENTS

7.2.2.1 OBETICHOLIC ACID

7.2.2.2 TGF-Β INHIBITORS

7.2.2.3 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) INHIBITORS

7.2.2.4 LYSYL OXIDASE-LIKE 2 (LOXL2) INHIBITORS

7.2.2.5 OTHERS

7.2.3 ANTI-INFLAMMATORY DRUGS

7.2.3.1 CORTICOSTEROIDS

7.2.3.1.1 PREDNISONE

7.2.3.1.2 DEXAMETHASONE

7.2.3.2 TUMOR NECROSIS FACTOR (TNF) INHIBITORS

7.2.3.2.1 INFLIXIMAB

7.2.3.2.2 ETANERCEPT

7.2.3.3 INTERLEUKIN (IL) INHIBITORS

7.2.3.3.1 IL-6 INHIBITORS (TOCILIZUMAB)

7.2.3.3.2 IL-1 INHIBITORS (ANAKINRA)

7.2.4 IMMUNOSUPPRESSANTS

7.2.4.1 MYCOPHENOLATE MOFETIL

7.2.4.2 TACROLIMUS

7.2.4.3 CYCLOSPORINE

7.2.5 MARKETED DRUGS

7.2.5.1 VELPATASVIR/SOFOSBUVIR

7.2.5.2 TENOFOVIR

7.2.5.3 LEDIPASVIR/SOFOSBUVIR

7.2.5.4 OBETICHOLIC ACID (OCA)

7.2.5.5 SOFOSBUVIR

7.2.5.6 PIRFENIDONE

7.2.5.7 OTHERS

7.2.6 PIPELINE DRUGS

7.2.7 BRANDED DRUGS

7.2.7.1 EPCLUSA

7.2.7.2 VIREAD AND VEMLIDY

7.2.7.3 OCALIVA

7.2.7.4 HARVONI

7.2.7.5 SOVALDI

7.2.7.6 BARACLUDE

7.2.7.7 ACTOS

7.2.7.8 OTHERS

7.2.8 GENERIC DRUGS

7.2.9 ORAL

7.2.10 PARENTERAL

7.2.11 OTHERS

7.3 SURGERY/THERAPY

7.3.1 LIVER TRANSPLANTATION

7.3.2 ORTHOTOPIC LIVER TRANSPLANT (OLT)

7.3.3 LIVING DONOR LIVER TRANSPLANT (LDLT)

7.3.4 SPLIT LIVER TRANSPLANTATION

7.3.5 DOMINO LIVER TRANSPLANT

7.3.6 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES

7.3.6.1 ENDOSCOPIC VARICEAL LIGATION (EVL)

7.3.6.2 TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS)

7.3.6.3 LIVER ABLATION PROCEDURES

7.3.6.3.1 RADIOFREQUENCY ABLATION (RFA)

7.3.6.3.2 MICROWAVE ABLATION (MWA)

7.3.7 PARTIAL HEPATECTOMY (LIVER RESECTION)

7.3.7.1 SEGMENTAL RESECTION

7.3.7.2 LOBECTOMY

7.3.7.3 WEDGE RESECTION

7.3.8 CELL-BASED THERAPY

7.3.8.1 STEM CELL THERAPY

7.3.8.1.1 MESENCHYMAL STEM CELLS (MSCS)

7.3.8.1.2 HEMATOPOIETIC STEM CELLS (HSCS)

7.3.8.2 GENE THERAPY

7.3.8.2.1 CRISPR-BASED LIVER REGENERATION

7.3.8.2.2 HEPATIC STELLATE CELL (HSC) INHIBITORS

7.3.8.2.3 SIRNA-BASED THERAPIES

7.3.8.2.4 HEPATOCYTE APOPTOSIS INHIBITORS

7.3.8.2.4.1 OXIDATIVE STRESS INHIBITORS

7.3.8.2.4.2 EMRICASAN

7.3.8.2.4.3 PENTOXIFYLLINE

7.3.8.2.4.4 LOSARTAN

7.3.8.2.4.5 METHYL FERULIC ACID

7.3.8.2.4.6 OTHERS

7.4 OTHERS

8 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY STAGES

8.1 OVERVIEW

8.2 F2

8.3 F1

8.4 F3

8.5 F4

9 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY INDICATION

9.1 OVERVIEW

9.2 NON-ALCOHOLIC STEATOHEPATITIS (NASH)

9.3 HEPATITIS B & C-INDUCED FIBROSIS

9.3.1 CHRONIC HEPATITIS B VIRUS (HBV) FIBROSIS

9.3.2 CHRONIC HEPATITIS C VIRUS (HCV) FIBROSIS

9.4 ALCOHOLIC LIVER DISEASE (ALD)

9.5 AUTOIMMUNE LIVER DISEASES

9.5.1 AUTOIMMUNE HEPATITIS (AIH)

9.5.2 PRIMARY BILIARY CHOLANGITIS (PBC)

9.5.3 PRIMARY SCLEROSING CHOLANGITIS (PSC)

9.6 GENETIC DISORDERS

9.6.1 HEMOCHROMATOSIS

9.6.2 WILSON’S DISEASE

9.6.3 ALPHA-1 ANTITRYPSIN DEFICIENCY

9.7 OTHERS

10 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY GENDER

10.1 OVERVIEW

10.2 MALE

10.2.1 40-55 YEARS

10.2.2 ABOVE 55 YEARS

10.2.3 BELOW 40 YEARS

10.3 FEMALE

10.3.1 ABOVE 55 YEARS

10.3.2 40-55 YEARS

10.3.3 BELOW 40 YEARS

11 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.2.1 PUBLIC HOSPITALS

11.2.2 PRIVATE HOSPITALS

11.3 SPECIALTY CLINICS

11.3.1 HEPATOLOGY CLINICS

11.3.2 GASTROENTEROLOGY CLINICS

11.4 CLINICS

11.5 AMBULATORY AND RESEARCH CENTERS

11.6 OTHERS

12 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.2.1 RETAIL SALES

12.2.1.1 HOSPITAL PHARMACY

12.2.1.2 RETAIL PHARMACY

12.2.1.3 ONLINE PHARMACY

13 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY REGION

13.1 EUROPE

13.1.1 GERMANY

13.1.2 FRANCE

13.1.3 U.K.

13.1.4 ITALY

13.1.5 SPAIN

13.1.6 SWITZERLAND

13.1.7 RUSSIA

13.1.8 BELGIUM

13.1.9 NETHERLANDS

13.1.10 TURKEY

13.1.11 POLAND

13.1.12 SWEDEN

13.1.13 NORWAY

13.1.14 DENMARK

13.1.15 FINLAND

13.1.16 REST OF EUROPE

14 EUROPE LIVER FIBROSIS TREATMENT MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: GLOBAL

15 SWOT ANALYSIS

16 COMPANY PROFILES

16.1 GILEAD SCIENCES, INC.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENT/NEWS

16.2 ABBVIE, INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENT

16.3 MERCK & CO, INC.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENT

16.4 NOVARTIS AG

16.4.1 COMPANY SNAPSHOTS

16.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 PIPELINE PRODUCT PORTFOLIO

16.4.6 RECENT DEVELOPMENT

16.5 INTERCEPT PHARMACEUTICALS, INC.

16.5.1 COMPANY SNAPSHOTS

16.5.2 COMPANY SHARE ANALYSIS

16.5.3 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 PIPELINE PRODUCT PORTFOLIO

16.5.6 RECENT NEWS

16.6 ABBOTT

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 1.1.5 RECENT DEVELOPMENT

16.7 ALIGOS THERAPEUTICS

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENT

16.8 ALNICHE LIFE SCIENCES PVT. LTD.

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 ALENTIS THERAPEUTICS AG

16.9.1 COMPANY SNAPSHOT

16.9.2 PIPELINE PRODUCT PORTFOLIO

16.9.3 RECENT DEVELOPMENT

16.1 ADALTA LIMITED

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PIPELINE PRODUCT PORTFOLIO

16.10.4 RECENT NEWS

16.11 AKERO THERAPEUTICS, INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PIPELINE PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 BRISTOL-MYERS SQUIBB

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 CALLIDITAS THERAPEUTICS AB

16.13.1 COMPANY SNAPSHOT

16.13.2 PIPELINE PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENT

16.14 CUREVAC SE

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENT

16.15 CONATUSPHARMA

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT/NEWS

16.16 ENANTA PHARMACEUTICALS, INC.

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENT

16.17 ECHOSENS

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENT/NEWS

16.18 F. HOFFMANN-LA ROCHE LTD

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 COMPANY SHARE ANALYSIS

16.18.4 PRODUCT PORTFOLIO

16.18.5 RECENT DEVELOPMENT

16.19 GALECTO BIOTECH

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PIPELINE PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENT/NEWS

16.2 GALECTIN THERAPEUTICS, INC.

16.20.1 COMPANY SNAPSHOTS

16.20.2 REVENUE ANALYSIS AND SEGMENTAL ANALYSIS

16.20.3 PIPELINE PRODUCT PORTFOLIO

16.20.4 RECENT DEVELOPMENT

16.21 GYRE THERAPEUTICS, INC.

16.21.1 COMPANY SNAPSHOT

16.21.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.21.3 PRODUCT PORTFOLIO

16.21.4 RECENT DEVELOPMENT/NEWS

16.22 GENFIT SA

16.22.1 COMPANY SNAPSHOTS

16.22.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.22.3 PIPELINE PRODUCT PORTFOLIO

16.22.4 RECENT DEVELOPMENT

16.23 HEPION PHARMACEUTICALS

16.23.1 COMPANY SNAPSHOT

16.23.2 REVENUE ANALYSIS

16.23.3 PIPELINE PORTFOLIO

16.23.4 RECENT DEVELOPMENT

16.24 IPSEN PHARMA

16.24.1 COMPANY SNAPSHOT

16.24.2 REVENUE ANALYSIS

16.24.3 PIPELINE PRODUCT PORTFOLIO

16.24.4 RECENT NEWS/DEVELOPMENTS

16.25 LA RENON HEALTHCARE PVT. LTD.

16.25.1 COMPANY SNAPSHOT

16.25.2 PRODUCT PORTFOLIO

16.25.3 RECENT DEVELOPMENT

16.26 MADRIGAL PHARMACEUTICALS

16.26.1 COMPANY SNAPSHOTS

16.26.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.26.3 PRODUCT PORTFOLIO

16.26.4 RECENT DEVELOPMENT

16.27 NOVO NORDISK A/S

16.27.1 COMPANY SNAPSHOT

16.27.2 REVENUE ANALYSIS

16.27.3 PIPELINE PRODUCT PORTFOLIO

16.27.4 RECENT DEVELOPMENT

16.28 NOVOMEDIX

16.28.1 COMPANY SNAPSHOT

16.28.2 PIPELINE PRODUCT PORTFOLIO

16.28.3 RECENT DEVELOPMENT

16.29 PILANT THERAPEUTICS, INC.

16.29.1 COMPANY SNAPSHOT

16.29.2 REVENUE ANALYSIS

16.29.3 PIPELINE PRODUCT PORTFOLIO

16.29.4 RECENT NEWS

16.3 PFIZER INC.

16.30.1 COMPANY SNAPSHOT

16.30.2 REVENUE ANALYSIS

16.30.3 PIPELINE PRODUCT PORTFOLIO

16.30.4 RECENT DEVELOPMENT/NEWS

16.31 SAGIMET BIOSCIENCES

16.31.1 COMPANY SNAPSHOTS

16.31.2 REVENUE ANALYSIS

16.31.3 1.1.4 PRODUCT PORTFOLIO

16.31.4 RECENT DEVELOPMENT/NEWS

16.32 TAKEDA PHARMACEUTICAL COMPANY LIMITED

16.32.1 COMPANY SNAPSHOT

16.32.2 REVENUE ANALYSIS

16.32.3 PIPELINE PRODUCT PORTFOLIO

16.32.4 PRODUCT PORTFOLIO

16.32.5 RECENT DEVELOPMENT

16.33 TVARDI THERAPEUTICS

16.33.1 COMPANY SNAPSHOT

16.33.2 PIPELINE PRODUCT PORTFOLIO

16.33.3 RECENT DEVELOPMENT/NEWS

16.34 VERTEX PHARMACEUTICALS INCORPORATED

16.34.1 COMPANY SNAPSHOT

16.34.2 REVENUE ANALYSIS

16.34.3 PRODUCT PORTFOLIO

16.34.4 RECENT DEVELOPMENT

16.35 VIKING THERAPEUTICS

16.35.1 COMPANY SNAPSHOT

16.35.2 REVENUE ANALYSIS

16.35.3 PIPELINE PRODUCT PORTFOLIO

16.35.4 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

表格列表

TABLE 1 EUROPE INCIDENCE OF CIRRHOSIS BY GENDER (2019)

TABLE 2 TREATMENT ADHERENCE LEVELS IN LIVER DISEASE PATIENTS

TABLE 3 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 4 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 5 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 6 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 7 EUROPE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 8 EUROPE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 9 EUROPE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 10 EUROPE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 11 EUROPE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 12 EUROPE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 13 EUROPE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 14 EUROPE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 15 EUROPE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 16 EUROPE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 17 EUROPE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 18 EUROPE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 19 EUROPE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 20 EUROPE INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 EUROPE INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 22 EUROPE INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 23 EUROPE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 24 EUROPE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 25 EUROPE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 26 EUROPE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 27 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 28 EUROPE MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 29 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 30 EUROPE BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 31 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 32 EUROPE SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 33 EUROPE SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 34 EUROPE LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 35 EUROPE ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 36 EUROPE LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 37 EUROPE PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 38 EUROPE CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 39 EUROPE STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 40 EUROPE GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 41 EUROPE HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 42 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 43 EUROPE F2 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 44 EUROPE F1 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 45 EUROPE F3 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 46 EUROPE F4 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 47 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 48 EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 49 EUROPE HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 50 EUROPE HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 51 EUROPE ALCOHOLIC LIVER DISEASE (ALD) IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 52 EUROPE AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 53 EUROPE AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 54 EUROPE GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 55 EUROPE GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 56 EUROPE OTHERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 57 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 58 EUROPE MALE IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 59 EUROPE MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 60 EUROPE FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 61 EUROPE FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 62 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 63 EUROPE HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 64 EUROPE HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 65 EUROPE SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 66 EUROPE SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 EUROPE CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 68 EUROPE AMBULATORY AND RESEARCH CENTERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 69 EUROPE OTHERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 70 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 71 EUROPE DIRECT TENDER IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 72 EUROPE RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 73 EUROPE RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 74 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 75 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 76 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 77 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 78 EUROPE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 79 EUROPE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 80 EUROPE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 81 EUROPE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 EUROPE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 83 EUROPE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 84 EUROPE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 85 EUROPE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 86 EUROPE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 87 EUROPE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 88 EUROPE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 89 EUROPE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 90 EUROPE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 91 EUROPE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 92 EUROPE INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 93 EUROPE INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 94 TYPE

TABLE 95 EUROPE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 96 EUROPE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 97 EUROPE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 98 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 99 EUROPE MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 100 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 101 EUROPE BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 102 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 103 EUROPE SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 104 EUROPE LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 105 EUROPE ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 106 EUROPE LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 107 EUROPE PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 108 EUROPE CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 EUROPE STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 110 EUROPE GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 EUROPE HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 112 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 113 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 114 EUROPE HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 115 EUROPE AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 116 EUROPE GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 117 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 118 EUROPE MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 119 EUROPE FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 120 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 121 EUROPE HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 122 EUROPE SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 123 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 124 EUROPE RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 GERMANY LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 GERMANY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 127 GERMANY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 128 GERMANY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 129 GERMANY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 130 GERMANY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 131 GERMANY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 132 GERMANY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 133 GERMANY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 134 GERMANY ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 135 GERMANY ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 136 GERMANY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 GERMANY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 138 GERMANY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 139 GERMANY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 GERMANY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 141 GERMANY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 142 GERMANY INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 143 GERMANY INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 144 GERMANY INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 145 GERMANY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 146 GERMANY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 147 GERMANY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 148 GERMANY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 149 GERMANY MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 GERMANY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 151 GERMANY BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 152 GERMANY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 153 GERMANY SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 GERMANY LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 GERMANY ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 156 GERMANY LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 157 GERMANY PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 158 GERMANY CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 159 GERMANY STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 160 GERMANY GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 GERMANY HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 162 GERMANY LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 163 GERMANY LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 164 GERMANY HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 165 GERMANY AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 166 GERMANY GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 167 GERMANY LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 168 GERMANY MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 GERMANY FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 170 GERMANY LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 171 GERMANY HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 172 GERMANY SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 173 GERMANY LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 174 GERMANY RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 FRANCE LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 176 FRANCE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 177 FRANCE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 178 FRANCE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 FRANCE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 180 FRANCE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 181 FRANCE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 FRANCE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 183 FRANCE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 184 FRANCE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 185 FRANCE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 186 FRANCE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 187 FRANCE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 188 FRANCE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 189 FRANCE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 FRANCE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 191 FRANCE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 192 FRANCE INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 193 FRANCE INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 194 FRANCE INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 195 FRANCE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 FRANCE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 197 FRANCE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 198 FRANCE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 199 FRANCE MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 200 FRANCE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 201 FRANCE BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 202 FRANCE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 203 FRANCE SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 204 FRANCE LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 FRANCE ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 206 FRANCE LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 207 FRANCE PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 FRANCE CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 209 FRANCE STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 210 FRANCE GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 FRANCE HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 212 FRANCE LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 213 FRANCE LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 214 FRANCE HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 FRANCE AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 216 FRANCE GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 FRANCE LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 218 FRANCE MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 FRANCE FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 FRANCE LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 221 FRANCE HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 222 FRANCE SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 FRANCE LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 224 FRANCE RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 U.K. LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 226 U.K. MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 U.K. MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 228 U.K. ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 229 U.K. ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 230 U.K. ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 231 U.K. ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 232 U.K. ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 233 U.K. ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 234 U.K. ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 235 U.K. ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 236 U.K. CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 237 U.K. CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 238 U.K. CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 239 U.K. TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 240 U.K. TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 241 U.K. TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 242 U.K. INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 243 U.K. INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 244 U.K. INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 245 U.K. IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 U.K. IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 247 U.K. IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 248 U.K. MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 249 U.K. MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 250 U.K. MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 251 U.K. BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 U.K. MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 253 U.K. SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 254 U.K. LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 255 U.K. ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 U.K. LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 257 U.K. PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 258 U.K. CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 259 U.K. STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 260 U.K. GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 261 U.K. HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 262 U.K. LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 263 U.K. LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 264 U.K. HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 265 U.K. AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 U.K. GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 267 U.K. LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 268 U.K. MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 U.K. FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 U.K. LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 271 U.K. HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 272 U.K. SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 U.K. LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 274 U.K. RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 275 ITALY LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 276 ITALY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 277 ITALY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 278 ITALY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 ITALY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 280 ITALY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 281 ITALY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 282 ITALY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 283 ITALY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 284 ITALY ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 ITALY ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 286 ITALY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 287 ITALY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 288 ITALY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 289 ITALY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 290 ITALY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 291 ITALY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 292 ITALY INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 293 ITALY INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 294 ITALY INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 295 ITALY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 296 ITALY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 297 ITALY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 298 ITALY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 299 ITALY MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 ITALY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 301 ITALY BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 302 ITALY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 303 ITALY SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 304 ITALY LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 ITALY ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 ITALY LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 307 ITALY PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 308 ITALY CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 309 ITALY STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 310 ITALY GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 311 ITALY HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 312 ITALY LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 313 ITALY LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 314 ITALY HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 315 ITALY AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 316 ITALY GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 317 ITALY LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 318 ITALY MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 319 ITALY FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 320 ITALY LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 321 ITALY HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 322 ITALY SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 323 ITALY LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 324 ITALY RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 325 SPAIN LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 326 SPAIN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 SPAIN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 328 SPAIN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 SPAIN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 330 SPAIN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 331 SPAIN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 332 SPAIN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 333 SPAIN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 334 SPAIN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 335 SPAIN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 336 SPAIN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 SPAIN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 338 SPAIN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 339 SPAIN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 340 SPAIN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 341 SPAIN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 342 SPAIN INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 343 SPAIN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 344 SPAIN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 345 SPAIN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 346 SPAIN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 347 SPAIN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 348 SPAIN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 349 SPAIN MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 SPAIN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 SPAIN BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 352 SPAIN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 353 SPAIN SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 354 SPAIN LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 355 SPAIN ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 SPAIN LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 SPAIN PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 358 SPAIN CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 359 SPAIN STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 360 SPAIN GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 361 SPAIN HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 SPAIN LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 363 SPAIN LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 364 SPAIN HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 365 SPAIN AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 366 SPAIN GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 367 SPAIN LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 368 SPAIN MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 369 SPAIN FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 370 SPAIN LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 371 SPAIN HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 SPAIN SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 373 SPAIN LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 374 SPAIN RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 375 SWITZERLAND LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 376 SWITZERLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 377 SWITZERLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 378 SWITZERLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 379 SWITZERLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 380 SWITZERLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 381 SWITZERLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 382 SWITZERLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 383 SWITZERLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 384 SWITZERLAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 385 SWITZERLAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 386 SWITZERLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 387 SWITZERLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 388 SWITZERLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 389 SWITZERLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 390 SWITZERLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 391 SWITZERLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 392 SWITZERLAND INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 393 SWITZERLAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 394 SWITZERLAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 395 SWITZERLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 396 SWITZERLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 397 SWITZERLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 398 SWITZERLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 399 SWITZERLAND MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 400 SWITZERLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 401 SWITZERLAND BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 402 SWITZERLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 403 SWITZERLAND SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 404 SWITZERLAND LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 405 SWITZERLAND ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 406 SWITZERLAND LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 407 SWITZERLAND PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 408 SWITZERLAND CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 409 SWITZERLAND STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 410 SWITZERLAND GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 411 SWITZERLAND HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 412 SWITZERLAND LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 413 SWITZERLAND LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 414 SWITZERLAND HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 415 SWITZERLAND AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 416 SWITZERLAND GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 417 SWITZERLAND LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 418 SWITZERLAND MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 419 SWITZERLAND FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 420 SWITZERLAND LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 421 SWITZERLAND HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 422 SWITZERLAND SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 423 SWITZERLAND LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 424 SWITZERLAND RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 425 RUSSIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 426 RUSSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 427 RUSSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 428 RUSSIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 429 RUSSIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 430 RUSSIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 431 RUSSIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 432 RUSSIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 433 RUSSIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 434 RUSSIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 435 RUSSIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 436 RUSSIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 437 RUSSIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 438 RUSSIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 439 RUSSIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 440 RUSSIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 441 RUSSIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 442 RUSSIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 443 RUSSIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 444 RUSSIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 445 RUSSIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 446 RUSSIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 447 RUSSIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 448 RUSSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 449 RUSSIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 450 RUSSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 451 RUSSIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 452 RUSSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 453 RUSSIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 454 RUSSIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 455 RUSSIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 456 RUSSIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 457 RUSSIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 458 RUSSIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 459 RUSSIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 460 RUSSIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 461 RUSSIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 462 RUSSIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 463 RUSSIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 464 RUSSIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 465 RUSSIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 466 RUSSIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 467 RUSSIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 468 RUSSIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 469 RUSSIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 470 RUSSIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 471 RUSSIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 472 RUSSIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 473 RUSSIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 474 RUSSIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 475 BELGIUM LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 476 BELGIUM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 477 BELGIUM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 478 BELGIUM ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 479 BELGIUM ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 480 BELGIUM ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 481 BELGIUM ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 482 BELGIUM ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 483 BELGIUM ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 484 BELGIUM ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 485 BELGIUM ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 486 BELGIUM CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 487 BELGIUM CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 488 BELGIUM CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 489 BELGIUM TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 490 BELGIUM TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 491 BELGIUM TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 492 BELGIUM INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 493 BELGIUM INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 494 BELGIUM INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 495 BELGIUM IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 496 BELGIUM IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 497 BELGIUM IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 498 BELGIUM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 499 BELGIUM MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 500 BELGIUM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 501 BELGIUM BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 502 BELGIUM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 503 BELGIUM SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 504 BELGIUM LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 505 BELGIUM ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 506 BELGIUM LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 507 BELGIUM PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 508 BELGIUM CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 509 BELGIUM STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 510 BELGIUM GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 511 BELGIUM HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 512 BELGIUM LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 513 BELGIUM LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 514 BELGIUM HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 515 BELGIUM AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 516 BELGIUM GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 517 BELGIUM LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 518 BELGIUM MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 519 BELGIUM FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 520 BELGIUM LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 521 BELGIUM HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 522 BELGIUM SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 523 BELGIUM LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 524 BELGIUM RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 525 NETHERLANDS LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 526 NETHERLANDS MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 527 NETHERLANDS MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 528 NETHERLANDS ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 529 NETHERLANDS ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 530 NETHERLANDS ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 531 NETHERLANDS ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 532 NETHERLANDS ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 533 NETHERLANDS ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 534 NETHERLANDS ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 535 NETHERLANDS ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 536 NETHERLANDS CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 537 NETHERLANDS CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 538 NETHERLANDS CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 539 NETHERLANDS TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 540 NETHERLANDS TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 541 NETHERLANDS TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 542 NETHERLANDS INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 543 NETHERLANDS INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 544 NETHERLANDS INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 545 NETHERLANDS IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 546 NETHERLANDS IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 547 NETHERLANDS IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 548 NETHERLANDS MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 549 NETHERLANDS MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 550 NETHERLANDS MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 551 NETHERLANDS BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 552 NETHERLANDS MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 553 NETHERLANDS SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 554 NETHERLANDS LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 555 NETHERLANDS ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 556 NETHERLANDS LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 557 NETHERLANDS PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 558 NETHERLANDS CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 559 NETHERLANDS STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 560 NETHERLANDS GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 561 NETHERLANDS HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 562 NETHERLANDS LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 563 NETHERLANDS LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 564 NETHERLANDS HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 565 NETHERLANDS AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 566 NETHERLANDS GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 567 NETHERLANDS LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 568 NETHERLANDS MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 569 NETHERLANDS FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 570 NETHERLANDS LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 571 NETHERLANDS HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 572 NETHERLANDS SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 573 NETHERLANDS LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 574 NETHERLANDS RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 575 TURKEY LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 576 TURKEY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 577 TURKEY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 578 TURKEY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 579 TURKEY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 580 TURKEY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 581 TURKEY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 582 TURKEY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 583 TURKEY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 584 TURKEY ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 585 TURKEY ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 586 TURKEY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 587 TURKEY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 588 TURKEY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 589 TURKEY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 590 TURKEY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 591 TURKEY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 592 TURKEY INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 593 TURKEY INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 594 TURKEY INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 595 TURKEY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 596 TURKEY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 597 TURKEY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 598 TURKEY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 599 TURKEY MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 600 TURKEY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 601 TURKEY BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 602 TURKEY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 603 TURKEY SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 604 TURKEY LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 605 TURKEY ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 606 TURKEY LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 607 TURKEY PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 608 TURKEY CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 609 TURKEY STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 610 TURKEY GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 611 TURKEY HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 612 TURKEY LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 613 TURKEY LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 614 TURKEY HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 615 TURKEY AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 616 TURKEY GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 617 TURKEY LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 618 TURKEY MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 619 TURKEY FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 620 TURKEY LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 621 TURKEY HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 622 TURKEY SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 623 TURKEY LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 624 TURKEY RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 625 POLAND LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 626 POLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 627 POLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 628 POLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 629 POLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 630 POLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 631 POLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 632 POLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 633 POLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 634 POLAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 635 POLAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 636 POLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 637 POLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 638 POLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 639 POLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 640 POLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 641 POLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 642 POLAND INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 643 POLAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 644 POLAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 645 POLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 646 POLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 647 POLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 648 POLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 649 POLAND MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 650 POLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 651 POLAND BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 652 POLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 653 POLAND SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 654 POLAND LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 655 POLAND ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 656 POLAND LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 657 POLAND PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 658 POLAND CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 659 POLAND STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 660 POLAND GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 661 POLAND HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 662 POLAND LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 663 POLAND LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 664 POLAND HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 665 POLAND AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 666 POLAND GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 667 POLAND LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 668 POLAND MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 669 POLAND FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 670 POLAND LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 671 POLAND HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 672 POLAND SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 673 POLAND LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 674 POLAND RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 675 SWEDEN LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 676 SWEDEN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 677 SWEDEN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 678 SWEDEN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 679 SWEDEN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 680 SWEDEN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 681 SWEDEN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 682 SWEDEN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 683 SWEDEN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 684 SWEDEN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 685 SWEDEN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 686 SWEDEN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 687 SWEDEN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 688 SWEDEN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 689 SWEDEN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 690 SWEDEN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 691 SWEDEN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 692 SWEDEN INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 693 SWEDEN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 694 SWEDEN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 695 SWEDEN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 696 SWEDEN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 697 SWEDEN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 698 SWEDEN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 699 SWEDEN MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 700 SWEDEN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 701 SWEDEN BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 702 SWEDEN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 703 SWEDEN SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 704 SWEDEN LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 705 SWEDEN ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 706 SWEDEN LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 707 SWEDEN PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 708 SWEDEN CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 709 SWEDEN STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 710 SWEDEN GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 711 SWEDEN HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 712 SWEDEN LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 713 SWEDEN LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 714 SWEDEN HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 715 SWEDEN AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 716 SWEDEN GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 717 SWEDEN LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 718 SWEDEN MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 719 SWEDEN FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 720 SWEDEN LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 721 SWEDEN HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 722 SWEDEN SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 723 SWEDEN LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 724 SWEDEN RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 725 NORWAY LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 726 NORWAY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 727 NORWAY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 728 NORWAY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 729 NORWAY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 730 NORWAY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 731 NORWAY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 732 NORWAY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 733 NORWAY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 734 NORWAY ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 735 NORWAY ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 736 NORWAY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 737 NORWAY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 738 NORWAY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 739 NORWAY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 740 NORWAY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 741 NORWAY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 742 NORWAY INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 743 NORWAY INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 744 NORWAY INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 745 NORWAY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 746 NORWAY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 747 NORWAY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 748 NORWAY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 749 NORWAY MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 750 NORWAY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 751 NORWAY BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 752 NORWAY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 753 NORWAY SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 754 NORWAY LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 755 NORWAY ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 756 NORWAY LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 757 NORWAY PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 758 NORWAY CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 759 NORWAY STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 760 NORWAY GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 761 NORWAY HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 762 NORWAY LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 763 NORWAY LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 764 NORWAY HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 765 NORWAY AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 766 NORWAY GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 767 NORWAY LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 768 NORWAY MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 769 NORWAY FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 770 NORWAY LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 771 NORWAY HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 772 NORWAY SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 773 NORWAY LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 774 NORWAY RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 775 DENMARK LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 776 DENMARK MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 777 DENMARK MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 778 DENMARK ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 779 DENMARK ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 780 DENMARK ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 781 DENMARK ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 782 DENMARK ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 783 DENMARK ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 784 DENMARK ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 785 DENMARK ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 786 DENMARK CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 787 DENMARK CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 788 DENMARK CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 789 DENMARK TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 790 DENMARK TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 791 DENMARK TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 792 DENMARK INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 793 DENMARK INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 794 DENMARK INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 795 DENMARK IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 796 DENMARK IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 797 DENMARK IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 798 DENMARK MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 799 DENMARK MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 800 DENMARK MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 801 DENMARK BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 802 DENMARK MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 803 DENMARK SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 804 DENMARK LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 805 DENMARK ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 806 DENMARK LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 807 DENMARK PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 808 DENMARK CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 809 DENMARK STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 810 DENMARK GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 811 DENMARK HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 812 DENMARK LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 813 DENMARK LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 814 DENMARK HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 815 DENMARK AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 816 DENMARK GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 817 DENMARK LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 818 DENMARK MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 819 DENMARK FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 820 DENMARK LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 821 DENMARK HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 822 DENMARK SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 823 DENMARK LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 824 DENMARK RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 825 FINLAND LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 826 FINLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 827 FINLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 828 FINLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 829 FINLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 830 FINLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 831 FINLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 832 FINLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 833 FINLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 834 FINLAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 835 FINLAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 836 FINLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 837 FINLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 838 FINLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 839 FINLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 840 FINLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 841 FINLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 842 FINLAND INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 843 FINLAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 844 FINLAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 845 FINLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 846 FINLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 847 FINLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 848 FINLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 849 FINLAND MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 850 FINLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 851 FINLAND BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 852 FINLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 853 FINLAND SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 854 FINLAND LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 855 FINLAND ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 856 FINLAND LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 857 FINLAND PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 858 FINLAND CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 859 FINLAND STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 860 FINLAND GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 861 FINLAND HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 862 FINLAND LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 863 FINLAND LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 864 FINLAND HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 865 FINLAND AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 866 FINLAND GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 867 FINLAND LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 868 FINLAND MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 869 FINLAND FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 870 FINLAND LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 871 FINLAND HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 872 FINLAND SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 873 FINLAND LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 874 FINLAND RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 875 REST OF EUROPE LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

图片列表

FIGURE 1 EUROPE LIVER FIBROSIS TREATMENT MARKET: SEGMENTATION

FIGURE 2 EUROPE LIVER FIBROSIS TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE LIVER FIBROSIS TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 EUROPE LIVER FIBROSIS TREATMENT MARKET: REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE LIVER FIBROSIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE LIVER FIBROSIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE LIVER FIBROSIS TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE LIVER FIBROSIS TREATMENT MARKET: MARKET END USER COVERAGE GRID..

FIGURE 9 EUROPE LIVER FIBROSIS TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE LIVER FIBROSIS TREATMENT MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE OF LIVER DISEASES IS EXPECTED TO DRIVE THE GROWTH OF EUROPE LIVER FIBROSIS TREATMENT MARKET FROM 2025 TO 2032

FIGURE 12 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LIVER FIBROSIS TREATMENT MARKET IN 2025-2032

FIGURE 13 TWO SEGMENTS COMPRISE THE EUROPE LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE

FIGURE 14 EUROPE LIVER FIBROSIS TREATMENT MARKET: EXECUTIVE SUMMARY

FIGURE 15 STRATEGIC DECISIONS

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE LIVER FIBROSIS TREATMENT MARKET

FIGURE 17 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, 2024

FIGURE 18 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)

FIGURE 19 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)

FIGURE 20 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 21 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY STAGES, 2024

FIGURE 22 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY STAGES, 2025-2032 (USD THOUSAND)

FIGURE 23 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY STAGES, CAGR (2025-2032)

FIGURE 24 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY STAGES, LIFELINE CURVE

FIGURE 25 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, 2024

FIGURE 26 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, 2025-2032 (USD THOUSAND)

FIGURE 27 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, CAGR (2025-2032)

FIGURE 28 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 29 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY GENDER, 2024

FIGURE 30 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)

FIGURE 31 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY GENDER, CAGR (2025-2032)

FIGURE 32 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 33 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY END USER, 2024

FIGURE 34 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)

FIGURE 35 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY END USER, CAGR (2025-2032)

FIGURE 36 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 37 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2024

FIGURE 38 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)

FIGURE 39 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)

FIGURE 40 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 41 EUROPE LIVER FIBROSIS TREATMENT MARKET: SNAPSHOT (2024)

FIGURE 42 EUROPE LIVER FIBROSIS TREATMENT MARKET: COMPANY SHARE 2024 (%)

查看详细信息 Right Arrow

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。

Frequently Asked Questions

The Europe liver fibrosis treatment market size was valued at USD 5.06 billion in 2024.
The Europe liver fibrosis treatment market is to grow at a CAGR of 10.3% during the forecast period of 2025 to 2032.
The Europe liver fibrosis treatment market is segmented into five notable segments based on treatment type, stages, indication, end user, and distribution channel. On the basis of treatment type, the market is segmented into medication and surgery/therapy. on the basis of stages, the market is segmented into F2, F1, F3, and F4, on the basis of indication, the market is segmented into non-alcoholic steatohepatitis (Nash), hepatitis B & C-induced fibrosis, alcoholic liver disease (ALD), autoimmune liver diseases, genetic disorders, and others. on the basis of gender, the market is segmented into male and female. on the basis of end user, the market is segmented into hospitals, specialty clinics, clinics, ambulatory and research centers, and others. on the basis of distribution channel, the market is segmented into direct tender and retail sales.
Companies such as Gilead Sciences, Inc. (U.S.),AbbVie Inc. (U.S.),Merck & Co., Inc. (U.S.),Novartis AG (Switzerland), Intercept Pharmaceuticals, Inc. (U.S.)are the major companies in the europe liver fibrosis treatment.
In October 2024, Intercept Pharmaceuticals, Inc discussed their ongoing efforts to explore racial differences and disparities in Primary Biliary Cholangitis (PBC) care. The company is addressing how various populations may face different challenges in the diagnosis, treatment, and management of PBC. By exploring these disparities, Intercept aims to improve access to care and treatment outcomes for all patients, potentially reducing barriers to effective treatment of liver diseases, including fibrosis.
The countries covered in the Europe liver fibrosis treatment are Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Netherlands, Switzerland, Norway, Austria, Ireland, and rest of Europe.
Germany is expected to dominate the Europe liver fibrosis treatment market, particularly in North America, due to advanced healthcare infrastructure, high disease prevalence, robust research funding, presence of leading pharmaceutical companies, and rapid adoption of innovative treatment solutions.
Germany is expected to witness the highest CAGR in the Europe liver fibrosis treatment market, driven by rising disease prevalence, healthcare reforms, and increased R&D.
The primary challenges include long-term follow-ups associated with liver fibrosis treatment, high costs, limited curative options, and patient adherence issues.
Increasing prevalence of liver diseases , is emerging as a pivotal trend driving the Europe liver fibrosis treatment.
The major factors driving the growth of Europe liver fibrosis treatment are rising consumption of alcohol, rising liver transplantation rates, and growing incidence of non-alcoholic fatty liver disease (NAFLD) & NASH.
The treatment type segment is expected to dominate the Europe liver fibrosis treatment market in 2025 due to increasing demand for effective therapies, ongoing clinical trials, and rising approvals of novel drugs.

浏览相关页面

Banner
Testimonial
Image
David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.
Image
Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Image
Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Image
Business Intelligence and Analytics, Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst, Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director, Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

Image
COO, A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director, Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager, Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations, GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst, Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager, Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Image
Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Image
Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future